“Bio-Betters” Could Be Good Business, But It’s Not For Genzyme – Termeer
Executive Summary
Follow-on biologics that improve upon the originator drug could be developed into a good business but "that's not where we are choosing to go," Genzyme CEO Henri Termeer said at the Goldman Sachs Healthcare CEOs Unscripted conference Jan. 7